Molecular imaging of brain amyloid in mild cognitive impairment and Alzheimer's disease (original) (raw)

Nature Clinical Practice Neurology volume 3, pages 366–367 (2007)Cite this article

boxed-textSmall GW et al. (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355: 2652–2663

Background

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Petersen RC et al. (2001) Current concepts in mild cognitive impairment. Arch Neurol 58: 1985–1992
    Article CAS Google Scholar
  2. Cummings JL (2004) Alzheimer's Disease. New Engl J Med 351: 56–67
    Article CAS Google Scholar
  3. Lockhart A (2006) Imaging Alzheimer's disease pathology: one target, many ligands. Drug Discov Today 11: 1093–1099
    Article CAS Google Scholar
  4. Kantarci K and Jack CR Jr (2003) Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am 13: 197–209
    Article Google Scholar
  5. Engler H et al. (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129: 2856–2866
    Article Google Scholar

Download references

Acknowledgements

The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. GSK Clinical Imaging Centre, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK paul.m.matthews@gsk.com

Authors and Affiliations

  1. PM Matthews is Vice-President for Imaging, Genetics and Neurology at GlaxoSmithKline and Head of the GSK Clinical Imaging Centre, Hammersmith Hospital, London, UK.,
    Paul M Matthews

Authors

  1. Paul M Matthews
    You can also search for this author inPubMed Google Scholar

Ethics declarations

Competing interests

Paul M Matthews is employed by GlaxoSmithKline, which is developing therapies for Alzheimer's disease that should have applications in people with mild cognitive impairment. GlaxoSmithKline is closely collaborating with Siemens in aspects of molecular imaging.

Rights and permissions

About this article

Cite this article

Matthews, P. Molecular imaging of brain amyloid in mild cognitive impairment and Alzheimer's disease.Nat Rev Neurol 3, 366–367 (2007). https://doi.org/10.1038/ncpneuro0520

Download citation